An expert panel of the EU drug regulator, the European Medicines Agency (EMA), endorsed seven new medicines for approval this ...

The U.S. is in "big danger" of falling behind in vaccine technology research as government funding declines and vaccine ...

Revenue -- $1.9 billion reported for the quarter, compared to prior sales cycles impacted by earlier U.S. COVID-19 vaccine ...

It may feel like you are surrounded by sniffles and coughs, but flu season activity is still low in many parts of the U.S.

Investors watching the global biotech race may be sensing a shift after Moderna (NASDAQ:MRNA) co-founder and chairman Noubar ...

Moderna's narrative is shifting as analysts modestly trim their fair value from $37.32 to $35.78 per share and nudge the ...

The FDA is reportedly preparing to add what's known as a "black box" warning to Covid shots by the end of the year, marking a ...

Moderna is down 34.5% since the beginning of the year, and at $27.52 per share, it is trading 42.1% below its 52-week high of ...

IMA203CD8 is a second-generation PRAME cell therapy with enhanced pharmacology in ongoing Phase 1a dose escalationManageable ...

Moderna has tapped Swedish long-acting drug formulation company Nanexa to improve the delivery of up to five injectable ...

Moderna is seeking to enhance some of its drugs with Nanexa’s technology as the biologics sector moves to less frequent ...